Both Darbepoetin Alfa and Carbamylated Erythropoietin Prevent Kidney Graft Dysfunction Due to Ischemia/Reperfusion in Rats

Background. Ischemia/reperfusion (I/R) injury is an important cause of renal graft dysfunction. Increases in cold and warm ischemia times lead to a higher risk of early posttransplant complications including delayed graft function and acute rejection. Moreover, prolonged cold ischemia is a predictor of long-term graft loss in kidney transplant patients. Methods. Darbepoetin alfa (DA) and carbamylated nonerythropoietic derivative of erythropoietin (CEPO) protective effects were evaluated in a model of I/R injury after kidney transplantation in both syngeneic and allogeneic combinations. The effects of wortmannin (phosphorylated Akt [p-Akt] inhibitor) administration were also investigated. Serum creatinine was evaluated at 16, 24, 48 hr and at 4 and 7 days posttransplant. Animals were killed 24 hr or 7 days after transplant and kidneys were processed for histological analysis, immunohistochemistry assessment of erythropoietin receptor (EPOR) and &bgr;-common chain receptor expression, granulocyte infiltration, nitrotyrosine staining, p-Akt expression, peritubular capillary (PTC) density, apoptosis, antioxidant, and antiapoptotic gene expression. Results. DA and CEPO significantly reduced serum creatinine, tubular injury, tubular nitrotyrosine staining, and prevented I/R-induced tubular apoptosis, but only when given both to the donor and to the recipient. DA and CEPO cytoprotection was associated with prevention of I/R-induced drop of p-Akt expression in tubuli, and almost complete preservation of capillary density in the tubulointerstitium of the graft. CEPO was more effective than DA in reducing tubular oxidative stress and preserving PTCs. Conclusion. DA and CEPO when given both to the donor and to the recipient, prevented renal graft dysfunction, tubular oxidative stress, and apoptosis after I/R injury in kidney transplantation. Their cytoprotection was mediated by tubular p-Akt activation and PTC density preservation.

[1]  U. Neumann,et al.  rHuEPo Reduces Ischemia-Reperfusion Injury and Improves Survival After Transplantation of Fatty Livers in Rats , 2010, Transplantation.

[2]  G. Heinze,et al.  Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study , 2009, BMJ : British Medical Journal.

[3]  W. Fried,et al.  Erythropoietin and erythropoiesis. , 2009, Experimental hematology.

[4]  K. Jang,et al.  Peritubular capillary preservation with COMP-angiopoietin-1 decreases ischemia-reperfusion-induced acute kidney injury. , 2009, American journal of physiology. Renal physiology.

[5]  U. Neumann,et al.  Erythropoietin reduces ischemia‐reperfusion injury after liver transplantation in rats , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[6]  A. Canbay,et al.  Erythropoietin Treatment Improves Liver Regeneration and Survival in Rat Models of Extended Liver Resection and Living Donor Liver Transplantation , 2008, Transplantation.

[7]  A. Cerami,et al.  Erythropoietin‐mediated tissue protection: reducing collateral damage from the primary injury response , 2008, Journal of internal medicine.

[8]  R. Califf,et al.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. , 2008, Kidney international.

[9]  N. Ichimaru,et al.  Carbamylated Erythropoietin Improves Angiogenesis and Protects the Kidneys from Ischemia-Reperfusion Injury , 2008, Cell transplantation.

[10]  T. Fabian,et al.  Efficacy and safety of epoetin alfa in critically ill patients. , 2007, The New England journal of medicine.

[11]  T. Okada,et al.  Asialoerythropoietin Has Strong Renoprotective Effects Against Ischemia-Reperfusion Injury in a Murine Model , 2007, Transplantation.

[12]  N. Ichimaru,et al.  Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. , 2007, Biochemical and biophysical research communications.

[13]  A. Cerami,et al.  Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia , 2006, Proceedings of the National Academy of Sciences.

[14]  H. Matsubara,et al.  Erythropoietin-Mobilized Endothelial Progenitors Enhance Reendothelialization via Akt–Endothelial Nitric Oxide Synthase Activation and Prevent Neointimal Hyperplasia , 2006, Circulation research.

[15]  S. Fuggle,et al.  Major effects of delayed graft function and cold ischaemia time on renal allograft survival. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  Z. Endre,et al.  Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. , 2006, Kidney international.

[17]  I. Tsouchnikas,et al.  Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  P. Daly,et al.  Delayed graft function: a dilemma in renal transplantation , 2005, BJU international.

[19]  G. Remuzzi,et al.  Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. , 2005, Kidney international.

[20]  P. Ghezzi,et al.  A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Ortiz de Montellano,et al.  Protein kinase Akt/PKB phosphorylates heme oxygenase‐1 in vitro and in vivo , 2004, FEBS letters.

[22]  Giuseppe Remuzzi,et al.  Delayed graft function in kidney transplantation , 2004, The Lancet.

[23]  N. Patel,et al.  Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. , 2004, Kidney international.

[24]  D. Allen,et al.  Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. , 2004, Journal of the American Society of Nephrology : JASN.

[25]  Z. Erbayraktar,et al.  Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.

[26]  D. Fliser,et al.  Low-Dose Therapy With the Long-Acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure , 2004, Circulation.

[27]  David W. Johnson,et al.  Erythropoietin protects against ischaemic acute renal injury. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  A. Salahudeen,et al.  Cold ischemia and the reduced long-term survival of cadaveric renal allografts. , 2004, Kidney international.

[29]  D. Basile.  Rarefaction of peritubular capillaries following ischemic acute renal failure: a potential factor predisposing to progressive nephropathy , 2004, Current opinion in nephrology and hypertension.

[30]  Chul-woo Yang,et al.  Preconditioning with erythropoietin protects against subsequent ischemia‐reperfusion injury in rat kidney , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  M. Mitsnefes,et al.  ACTIVATION OF MITOCHONDRIAL APOPTOTIC PATHWAYS IN HUMAN RENAL ALLOGRAFTS AFTER ISCHEMIA‐REPERFUSION INJURY , 2003, Transplantation.

[32]  Yili Yang,et al.  Regulation of apoptosis: the ubiquitous way , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[34]  D. Basile,et al.  Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. , 2001, American journal of physiology. Renal physiology.